1 / 13

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High S

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein. The PIOSTAT Study.

ostinmannual
Download Presentation

Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High S

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein The PIOSTAT Study Markolf Hanefeld, MD, PhD; Nikolaus Marx, MD; Andreas Pfützner, MD, PhD; Werner Baurecht, MSc; Georg Lübben, MD; Efstrathios Karagiannis, MD; Ulf Stier, MD; Thomas Forst, MD Published in JACC January 23, 2007

  2. The PIOSTAT Study: Background • Markers of inflammation include high sensitivity C-reactive protein (hsCRP), matrix metalloproteinase (MMP)-9, and plasminogen activator inhibitor (PAI)-1. • Elevations of these markers have been associated with higher rates of future CV events. Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  3. The PIOSTAT Study: Background (cont.) • Statins are associated with a reduction in these inflammatory markers. • A new class of drugs, the thiazolidinediones (TZDs) (PPAR-γ agonists), have also been shown to have anti-inflammatory properties, reducing CRP, MMP-9, (MCP)-1, and soluble CD40L. • The TZD Pioglitazone has recently been associated with a reduction in cardiovascular endpoints in patients with type 2 diabetes mellitus. Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  4. The PIOSTAT Study: Background (cont.) • However, there is only scarce information on the benefits of treatment with TZDs, alone or in combination with statins, in patients with CVD and increased hs-CRP levels. • This study aimed to investigate the safety and efficacy of pioglitazone and simvastatin in combination versus each drug individually in non-diabetic subjects with CVD and elevated hs-CRP levels. Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  5. The PIOSTAT Study: Study Design 125 patients, ages 30-70 years, with CVD and/or HTN and hs-CRP level >1.0mg/l and <10 mg/l prior to randomization Prospective. Double-Blind. Randomized. Exclusion Criteria: Diabetes mellitus or chronic inflammatory diseases, statin therapy within 4 weeks, significant hepatic or renal disease, or CHF R Simvastatin Plus Pioglitazone 30 mg + 20 mg n=43 Simvastatin Monotherapy 20 mg n=43 Pioglitazone Monotherapy 30 mg n=39 after 2 wks after 2 wks after 2 wks 45 mg 40 mg 45 + 40 mg 6 week follow-up 6 week follow-up • Primary Endpoint: Changes in hs-CRP • Secondary Endpoint: MMP-9, MCP-1, PAI-1, cholesterol, triglycerides, glucose, HbA1c, Homeostasis Model Assessment (HOMA), Weight, BMI Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  6. The PIOSTAT Study: Baseline Characteristics Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  7. The PIOSTAT Study: Primary Endpoint Reduction in hs-CRP Levels at 12 weeks • There were no significant differences in the baseline levels of hs-CRP between the three groups. • At 12 weeks, pioglitazone and the combination regimen had an additive effect in reducing hs-CRP p<0.001 Reduction in hs-CRP (mg/l) n = 39 n = 43 n = 43 Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  8. The PIOSTAT Study: Primary Endpoint • The combination of pioglitazone plus simvastatin had additive effects on hs-CRP, with a 40% reduction from simvastatin monotherapy (p=0.01). • A subgroup analysis was performed in patients with and without metabolic syndrome (MetS), and the difference between monotherapy and combination therapy was only significant for simvastatin versus simvastatin plus pioglitazone in patients without metabolic syndrome. Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  9. The PIOSTAT Study: Secondary Endpoint Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  10. The PIOSTAT Study: Secondary Endpoint (Cont.) Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  11. The PIOSTAT Study: Secondary Endpoint (Cont.) Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  12. The PIOSTAT Study: Secondary Endpoints (Cont.) • Homeostasis Model Assessment (HOMA) decreased in those receiving pioglitazone monotherapy (p=0.003) and pioglitazone plus simvastatin (p<0.001). • The correlation between changes in HOMA and hs-CRP was significant in the piolgitazone monotherapy group (r=0.43; p=0.006). • The PAI-1 and MMP-9 also significantly decreased in the pioglitazone (monotherapy and combination with simvastatin) groups. Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

  13. The PIOSTAT Study: Summary • Pioglitazone and simvastatin exerted anti-inflammatory effects in non-diabetic patients with CVD and elevated hs-CRP. • Combining the two drugs resulted in an additive effect on low-grade inflammation, without a significant increase in serious adverse events. • For subgroups, the additive effect was only significant for patients without MetS. Hanefeld et al. JACC. 2007 Jan 23; 49(3):290-7.

More Related